Soligenix

NEWS
An updated webcast of the Soligenix Corporate Presentation, given by Dr. Christopher J. Schaber, President and CEO, is available on the Company website. To listen and view the presentation, please visit www.soligenix.com.
Analyst David Bautz, PhD of Zack’s Investment Research, Inc. updated coverage on Soligenix, Inc. on February 12, 2019. For more information, please visit SCR.Zacks.com.
Soligenix, Inc. announced the allowance of a new United States patent protecting its ricin toxin vaccine, RiVax®.
Although bioterrorism doesn’t get the kind of attention more traditional bombings and shootings receive, the biotech industry and the federal government are paying attention and actively funding and developing countermeasures to potential bioterror, military and public health emergencies.
Patent broadens protection in infectious disease, including composition of matter claims
Analyst Jason McCarthy, PhD of Maxim Group updated coverage on Soligenix, Inc. on December 6, 2018. For more information, please visit www.maximgrp.com.
Dr. Oreola Donini, Senior Vice President and Chief Scientific Officer, discusses the Company’s ricin toxin vaccine with ROI-NJ.
JOBS
IN THE PRESS